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ABSTRACT: Structurally unique 6,7-seco-ent-kaurenes, which are widely 
distributed in the genus Isodon, have attracted considerable attention because of their 
antitumor activities. Previously, a convenient conversion of commercially available 
oridonin (1) to 6,7-seco-ent-kaurenes was developed. Herein, several novel 
spiro-lactone-type ent-kaurene derivatives bearing various substituents at the C-1 and 
C-14 positions were further designed and synthesized from the natural product 
oridonin. Moreover, a number of seven-membered C-ring expanded 
6,7-seco-ent-kaurenes were also identified for the first time. It was observed that most 
of the spiro-lactone-type ent-kaurenes tested markedly inhibited the proliferation of 
cancer cells, with an IC50 value of as low as 0.55 μM. An investigation on its 
mechanism of action showed that the representative compound 7b affected the cell 
cycle and induced apoptosis at a low micromolar level in MCF-7 human breast cancer 
cells. Furthermore, compound 7b inhibited liver tumor growth in an in vivo mouse 
model and exhibited no observable toxic effects. Collectively, the results warrant 
further preclinical investigations of these spiro-lactone-type ent-kaurenes as potential 
novel anticancer agents. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Nature is an underexplored source of unique and desirable structural scaffolds for 
novel drug discovery.1 Many natural products and their derivatives have been 
developed successfully for clinical applications to treat human diseases in almost all 
therapeutic areas. Of the 112 first-in-class drugs approved by the U.S. Food and Drug 
Administration from 1999 to 2013, 31 (28%) were developed based on naturally 
occurring compounds.2  
The genus Isodon is well-known for producing bioactive diterpenoids with diverse 
carbon skeletons.3-5 More than 700 ent-kauranoids have been identified from the 
genus Isodon thus far, including mainly ent-kaurenes, 6,7-seco-ent-kaurenes, and 
8,9-seco-ent-kaurenes.6 Several ent-kaurenes like oridonin (1, Scheme 1) and its 
analogues have been studied extensively for the development of novel anticancer 
agents.7-11 Recently, there has been a growing interest in further investigating 
6,7-seco-ent-kaurene derivatives, which may be classified into the spiro-lactone and 
enmein-types (Figure 1), because of their broad range of bioactivities.12-14 In 
particularly, spiro-lactone-type ent-kaurenes bearing diverse chemical skeletons have 
exhibited promising antitumor activities.15,16  
However, for these complex 6,7-seco-ent-kaurenes, their isolation from Isodon 
plants in only low yields cannot meet the need for further developmental laboratory 
studies, while their total synthesis is also quite challenging due to the several 
stereogenic centers present.17 In previous work, a convenient conversion of the 
commercially available oridonin (1) to 6,7-seco-ent-kaurenes was developed in high 
yield.18-20 A series of spiro-lactone-type and enmein-type ent-kaurenes with diverse 
chemical properties and potential anticancer activities was synthesized in our 
laboratory.21,22 Among these compounds, several spiro-lactone-type derivatives have 
been shown to inhibit the proliferation of cancer cells, and some were found to be 
more potent than their parent compound, oridonin (1).23 
 
 
 Figure 1. Structures of representative spiro-lactone and enmein-type ent-kaurenes 
isolated from plants. 
 
Based on these promising results and the ongoing interest in 6,7-seco-ent-kaurenes 
in the search for anticancer drug candidates with new skeletons, potent antitumor 
activities, and less toxic effects,24,25 several new spiro-lactone-type ent-kaurene 
derivatives bearing various substitutions at the C-1 and C-14 positions have been 
produced from the commercially available oridonin (1), and evaluated for their 
potential anticancer activities. In addition, the mechanism of action of the 
representative compound 7b was investigated in detail. 
 
RESULTS AND DISCUSSION 
Chemistry. Based on the previous structure-activity relationships (SARs) 
established,26,27 compounds 6, 10, and 12 were designed initially by introducing 
preferred moieties like an alkenyl unit to enhance the resultant activity. The synthesis 
of the spiro-lactone-type ent-kaurenes is outlined in Schemes 1 and 2. Protection of 
the 7,14-dihydroxy group of oridonin (1) with 2,2-dimethoxypropane afforded 
compound 2 in 95% yield. The 1-hydroxy group of compound 2 was then selectively 
activated by MsCl, which was eliminated subsequently in the presence of Li2CO3 and 
LiBr in DMF at 110 oC to provide the 1-ene 4 in 75% yield.28 The removal of the 
acetonide group in the 4 with 10% HCl aqueous solution gave compound 5 in 90% 
yield. The conversion of compound 5 to the spiro-lactone-type ent-kaurene 6 was 
achieved successfully by lead tetraacetate oxidation. Compound 6 provided a good 
building block to construct a library of its 14-O-derivatives (7a-k) with diverse 
chemical properties. As shown in Scheme 2, synthon 4 was subjected to epoxidation 
through m-CPBA to give intermediate 8 in 71% yield. The removal of the protecting 
group with 5% H2SO4 provided the desired analogue 9 bearing a C-1,2-epoxy group 
in 87% yield. The subsequent 6,7-ring opening reaction of compound 9 led to the 
generation of compound 10 in 81% yield. On the other hand, the removal of the 
protecting group in 3 with 10% HCl aqueous solution afforded compound 11, which 
was further converted to 6,7-seco-kaurene 12 using lead tetraacetate in 79% yield. 
Some derivatives of compound 12 were synthesized by treatment of this substance 
with various acids in the presence of DMAP and EDCI. 
 
Scheme 1. Synthesis of the 6,7-seco-ent-Kaurene 6 and Derivatives 7a-k 
  
Scheme 2. Synthesis of the 6,7-seco-ent-Kaurenes 10 and 12 and Derivatives 13a-d 
  
In previous studies, starting from commercially available oridonin (1), the 
enmein-type diterpenoid 14 was obtained by treatment with sodium periodate in water 
(Scheme 3).18 Further oxidation of 14 with Jones reagent at 0 oC afforded the 
corresponding ketone 17 in a total yield of 85%. In the present investigation, further 
treatment of compounds 14 and 17 with 10% HCl provided the new seven-membered 
C-ring-expanded analogues 15 and 18, respectively. A possible mechanism for the 
formation of these ring-expanded analogues is acid-catalyzed retroaldol condensation 
and subsequent isomerization to adopt a more stable structure (Scheme 4). The unique 
skeleton of compound 15, which contains a seven-membered ring, was identified 
using 2D-NMR spectroscopy. This type of diterpenoid, bearing a seven-membered 
ring is rare in Nature, and it may be worthy of further extensive biological evaluation. 
 
Scheme 3. Synthesis of the C-Ring-expanded Kaurenes 15, 16, and 18 
  
Scheme 4. Mechanism of Conversion from Oridonin (1) to the C-Ring-expanded 
ent-Kaurene 15 
 
 
Structural Identification. During the 1970s and the early 1980s, it was difficult to 
discriminate between the enmein-type and spiro-lactone-type ent-kaurenes due to the 
lack of sufficiently sensitive NMR spectroscopic methods. For this reason, some 
spiro-lactone-type compounds were misidentified as enmein-type compounds. In the 
present study, the structure of the spiro-lactone-type compound 6 was established 
unambiguously from its 2D NMR spectra. Its molecular formula was determined to be 
C20H24O5, with nine indices of hydrogen deficiency by HRESIMS ([M+Na]
+, 
367.1520). The 1H NMR spectrum showed the presence of a formyl group proton 
doublet (δH 9.85, 1H, d, J = 4.65 Hz), two exocyclic methylenes (δH 6.22 and δH 5.62) 
and two oxygen-bearing methylenes (δH 4.35 and δH 4.74). The 13C NMR spectrum 
showed the presence of 20 carbon resonances that were classified as six quaternary 
carbons, seven methines, five methylenes, and two methyl groups (Table S1, 
Supporting Information). The key HMBC cross-peaks of H-6 (δH 9.85) with C-5 (δc 
58.7) indicated the attachment of the –CHO moiety at C-5. Moreover, the linkage 
between C-7 and C-20 via a lactone was supported by the HMBC cross-peaks of 
H2-20 (δH 4.35 and δH 4.74) with C-7 (δC 172.8) (Figure 2). Consequently, after 
careful comparison of the 1H and 13C NMR data of compounds 5 and 6, compound 6 
was assigned structurally as 
ent-6,7,15-trioxo-7,20-epoxy-14β-hydroxy-1-alkene-6,7-seco-16-kaurene. 
The structure of the enmein-type diterpenoid 14 was determined in a previous 
study,19 and the gross structure of 15 was elucidated by the analysis of 2D NMR data 
and by comparison with the NMR data of 14. The 1H NMR spectrum of 15 exhibited 
three singlets at δH 0.96, 1.05 and 2.34 (Table S2, Supporting Information). After 
comparison with the NMR data of 14 and 15, a singlet signal at δH 2.34 (3H, s) was 
attributed to the methyl group at the C-ring, which was isomerized from an exocyclic 
methylene. Additionally, a deshielded singlet (δH 13.99, 1H, s) was observed, and this 
was attributed to a stable enol due to the presence of an adjacent lactone system. In 
the HMBC spectrum, a series of key correlations were observed clearly to support the 
proposed structure: H-14 with C-12 and 13, H-17 with C-13, and OH-15 with C-8 and 
16 (Figure 2).  
 
 
Figure 2. Key 1H-1H COSY and HMBC correlations of compounds 6 and 15. 
 
Antiproliferative Effects on Human Cancer Cells. The in vitro antiproliferative 
activities of representative 6,7-seco-ent-kaurenes were screened with human 
hepatocellular carcinoma Bel-7402 cells using the MTT method (Figure S1, 
Supporting Information). The results showed that the newly synthesized 
spiro-lactone-type ent-kaurenes (6, 10, and 12) displayed antiproliferative activities. 
However, the ring-expanded compounds 15, 16, and 18 exhibited much weaker 
activities against Bel-7402 cells. These results inspired us to further evaluate the 
detailed antiproliferative activities of spiro-lactone-type kaurenes. As shown in Table 
1, although compound 6 in bearing a C-1,2-ene group possessed better cytotoxic 
potencies against these four types of cancer cells than its parent, oridonin (1), the 
introduction of an epoxy or a mesyl group into the A-ring of these diterpenoids (10 
and 12) caused a slight decrease in antiproliferative activities relative to 1. In previous 
studies, it was found that C-14 oxygenated derivatives of ent-kaurenes showed 
excellent cytotoxicities against human cancer cell lines.29 Therefore derivatives 7a-k 
and 13a-d were further synthesized and evaluated. Interestingly, most of these new 
C-14 oxygenated derivatives exhibited more potent cytotoxicities than their parent 
compounds (6 and 12), especially against Bel-7402 cells, with IC50 values that varied 
from 0.57 to 7.1 μM.  
 
Table 1. Antiproliferative Effects of 6,7-seco-ent-Kaurenes against Four Human 
Cancer Cell Linesa 
compound 
IC50 (μM)b 
MGC-803 Bel-7402 MCF-7 K562 
1 4.5±0.53 >10.0 9.1±0.86 5.1±0.62 
6 3.0±0.19 2.5±0.31 6.4±0.48 4.2±0.58 
7a 7.3±0.89 7.1±0.72 3.4±0.38 1.2±0.15 
7b 2.2±0.28 1.8±0.19 0.68±0.08 0.69±0.03 
7c 2.9±0.28 5.1±0.51 2.2±0.15 1.4±0.18 
7d 2.4±0.15 3.6±0.25 1.1±0.09 0.55±0.04 
7e 7.3±0.63 >10.0 6.4±0.89 1.0±0.08 
7f 0.95±0.07 0.57±0.07 1.0±0.07 0.63±0.03 
7g 4.3±0.32 2.2±0.17 3.3±0.21 5.5±0.62 
7h 2.8±0.12 1.3±0.10 3.5±0.36 2.9±0.32 
7i 0.95±0.05 1.5±0.09 1.5±0.11 1.3±0.10 
7j 1.3±0.06 0.84±0.06 1.2±0.17 0.78±0.06 
7k 2.8±0.11 1.3±0.23 2.0±0.18 1.9±0.20 
10 >10.0 4.6±0.39 >10.0 >10.0 
11 3.9±0.43 2.7±0.13 3.9±0.28 3.2±0.32 
12 >10.0 >10.0 >10.0 >10.0 
13a 4.5±0.54 3.1±0.22 5.5±0.72 6.2±0.43 
13b 3.2±0.21 2.2±0.16 3.7±0.21 4.5±0.32 
13c 3.4±0.23 1.1±0.12 2.9±0.42 1.7±0.23 
13d 8.8±0.68 3.8±0.23 9.5±0.12 1.2±0.15 
aMGC-803, human gastric cancer cells; Bel-7402, human hepatocellular carcinoma 
cells; MCF-7, human breast cancer cells; K562, human leukemia cells. bMTT method, 
with the cells incubated with the test compounds for 72 h (means ± SD, n = 3). 
 
 Antiproliferative Effects on Multidrug Resistant Cancer Cells. Multidrug 
resistance (MDR) is one of the major reasons for the failure of cancer chemotherapy.30 
To investigate whether these 6,7-seco-ent-kaurenes are effective against drug-resistant 
cancer cells, the representative derivatives 6 and 7b were selected to test their 
antiproliferative activities against drug-resistant and drug-sensitive parental cells, 
using the MTT method. The results showed that the antiproliferative activities of these 
synthesized compounds were more potent for the drug-resistant cells (KB/CP4; 
cisplatin resistant human cervix carcinoma) than for the KB-3-1 paired drug-sensitive 
cells (Table S3, Supporting Information). 
  
  Mechanism of Action Study of Compound 7b. The long-term antiproliferative 
ability of compound 7b was demonstrated initially after performing a colony 
formation assay (Figure S2, Supporting Information).31 To determine whether the 
suppression of cell growth by 7b is caused by a cell-cycle effect, the DNA content of 
the cell nuclei was detected by flow cytometry. As seen in Figure 3a, the cells 
accumulated at the G2/M phase and increased from 12.72% to 24.80% in a 
dose-dependent manner, with the percentages of cells in the S and G1 phases 
decreasing concomitantly. The above results suggested that 7b may inhibit cancer cell 
proliferation through cell cycle arrest at the G2/M phase. 
When MCF-7 and Bel-7402 cells were treated with compounds 6 and 7b for 24 h, 
lactate dehydrogenase (LDH) release into the culture medium was not observed 
(Figure S3, Supporting Information), suggesting that the inhibition of cell viability by 
these spiro-lactone-type diterpenoids was not by cytolysis, but most likely due to cell 
apoptosis.32 Thus, vehicle or 7b-treated MCF-7 cells were stained with Annexin V 
and propidium iodide (PI) followed by flow cytometic analysis. As shown in Figure 
3c, treatment with different concentrations of 7b (0, 0.25, 0.5, 1.0, and 2.0 μM) 
resulted in increased amounts of total apoptotic cells in a dose-dependent manner 
from 2.1% up to 38.7%.  
Mitochondria play an essential role in the process of apoptosis.33 The fluorescent 
probe JC-1 was used to measure the mitochondrial membrane potential (MMP) after 
the treatment of 7b. The results showed that 7b treatment in MCF-7 cells induced the 
dissipation of MMP in a dose-dependent manner, as indicated by a decrease in red 
fluorescence emission and an increase in green fluorescence emission (Figure S4, 
Supporting Information).  
Finally, Western blotting analysis was performed to evaluate the expression of 
apoptosis-related proteins.34 As shown in Figure 4, the results revealed that incubation 
with compound 7b dramatically increased the relative levels of Bax, caspase 3, 
p-ERK, and reduced the levels of Bcl-2 and P53 expression in a 
concentration-dependent manner.  
Taken together, these results demonstrated that 7b induced apoptosis in MCF-7 
cancer cells through a mitochondria-related apoptotic pathway. 
 
Figure 3. Compound 7b caused G2/M arrest and apoptosis of MCF-7 cancer cells. (a) 
MCF-7 cells were treated with DMSO and varying concentrations of 7b (0.25, 0.5, 
1.0, and 2.0 μM) for 48 h, then cells were harvested, stained with PI, and analyzed by 
flow cytometry; (b) Histograms displaying the percentage of cell cycle distribution; (c) 
MCF-7 cells were treated with varying concentrations of 7b (0.25, 0.5, 1.0, and 2.0 
μM). After 24 h of treatment, cells were collected and stained with Annexin V/PI, 
followed by flow cytometric analysis; (d) Histograms displaying the percentage of 
cell distribution. Data are represented as means ± SD of three independent 
experiments (*p < 0.05, **p < 0.01, and ***p < 0.001 vs. control group). 
 
 Figure 4. MCF-7 cells were treated with various concentrations of 7b (0, 0.5, 1.0, 2.0, 
and 4.0 μM) for 48 h. (a) The expression of p-ERK, pro-caspase-3, caspase-3, bcl-2, 
bax, and p53 was determined by Western blotting using specific antibodies. β-Actin 
was used as internal control; (b) The density ratio of proteins to β-actin is shown as 
relative expression. Data are represented as means ± SD of three independent 
experiments (*p <0.05, **p <0.01, ***p <0.001; control compared with 7b-treated 
cells).  
 
In Vivo Antitumor Activity of Compound 7b. To evaluate the in vivo antitumor 
activity of compound 7b, groups of mice were treated with 10 or 20 mg/kg of 
compound 7b or 20 mg/kg of oridonin (1) once a day, respectively. As shown in 
Figures 5a and 5b, treatment with 20 mg/kg of 7b enhanced the inhibitory effect on 
the tumor volume with an inhibition rate of 52.5%, which was equivalent to that of 
oridonin (1) (51.2%). When the mice were sacrificed at the end of the observation, the 
tumors were excised and weighed. The results also showed statistically significant 
reductions in tumor weight in both doses of the 7b-treated mice (Figure 5c). Moreover, 
there was no significant weight loss in mice treated with 7b when compared with 
those in the vehicle control group (Figure 5d). Taken together, these data indicated 
that compound 7b was efficacious in inhibiting the growth of liver cancer growth in 
vivo and may be worthy of further evaluation.  
  
Figure 5. Compound 7b exhibited antitumor activity in vivo. (a) H22 cells were 
inoculated subcutaneously into the right flank of mice. The mice were divided 
randomly into four groups (n = 8) and treated intravenously with 7b (20 mg/kg and 10 
mg/kg), oridonin (1, 20 mg/kg), and DMSO (dissolved in sodium chloride, control) 
each day for two weeks; (b) Visible tumor formation and photographs of tumors 
removed from mice at 14 days after initiation of treatment; (c) Treatment with 7b 
resulted in significant lower tumor weight compared with controls (***p <0.001); (d) 
Body weight changes of mice during treatment.  
 
In summary, several new spiro-lactone-type ent-kaurene derivatives with potent 
antiproliferative activities were synthesized from the commercially available 
diterpenoid oridonin (1). Furthermore, several C-ring expanded 6,7-seco-ent-kaurenes, 
each bearing a seven-membered ring, were also produced. The in vitro 
antiproliferative results showed that all the spiro-lactone-type 6,7-seco-ent-kaurenes 
inhibited the proliferation of cancer cells, but the seven-membered C-ring expanded 
6,7-seco-ent-kaurenes (15, 16, and 18) were inactive. It was found that the 
representative compound 7b caused cell-cycle arrest and induced apoptosis in MCF-7 
cells through a mitochondria-related apoptotic pathway, and the antitumor activity of 
compound 7b was verified in a liver cancer xenograft mouse model with no 
observable toxicity.  
 
EXPERIMENTAL SECTION 
General Experimental Procedures. Oridonin (1) was purchased from Nanjing 
Zelang Chemical Co., Ltd. (Zelang, People’s Republic of China) with a stated purity 
of 98%. All commercially available reagents were used without further purification. 
Anhydrous solvents were dried through routine protocols. 1H NMR and 13C NMR 
spectra were recorded with a Bruker AV-300 spectrometer (Bruker Company, 
Germany) in the indicated solvents (CDCl3 or DMSO-d6, TMS as internal standard): 
the values of the chemical shifts are expressed in δ values (ppm) and the coupling 
constants (J) in Hz. Low-and high-resolution mass spectrometry (ESIMS and 
HRESIMS) were measured on a Finnigan MAT 95 spectrometer (Finnigan, Germany). 
Flash column chromatography was carried out on 200-300 mesh silica gel purchased 
from Qingdao Haiyang Chemical Co., Ltd. (Qingdao, People’s Republic of China). 
Reactions were monitored by thin-layer chromatography (TLC) on 0.25 mm silica gel 
plates (GF254) and visualized under UV light.  
The general procedure for the synthesis of compounds 2-18 is provided in the 
Supporting Information, where full details of their purification and spectroscopic data 
are provided. Such information is given for compound 7b (testing biologically and 
mechanistically) below. 
ent-6,7,15-Trioxo-7,20-epoxy-(14β-O-p-flourobenzoyl)-1-alkene-6,7-seco-16-kaure
ne (7b). Compound 6 (72 mg, 0.2 mmol) was dissolved in dichloromethane, then 
EDCI, DMAP, and parafluorobenzoic acid (34 mg, 0.24 mmol) were added. The 
reaction mixture was stirred at room temperature for about 2 h. Then the mixture was 
washed with 10% HCl. The organic layer was washed with brine and dried over 
anhydrous Na2SO4. After flash chromatography (MeOH-CH2Cl2 1: 300, v/v), 
compound 7b was obtained as a white solid (48 mg, 69%): 1H NMR (CDCl3, 300 
MHz) δ 9.91 (1H, d, J = 5.7 Hz), 7.85 (2H, m), 6.98 (2H, t, J = 8.4 Hz), 6.21 (1H, s), 
5.99 (1H, m), 5.67 (2H, m), 5.47 (1H, s), 4.85, 4.60 (each 1H, dd, JA = JB = 10.8 Hz), 
3.32 (1H, s), 2.27 (1H, m), 2.21 (1H, m), 1.97 (1H, d, J = 5.7 Hz), 1.88 (3H, m), 1.59 
(3H, m), 1.18 (3H, s), 0.91 (3H, s); 13C NMR (CDCl3, 75 MHz) δ 203.6, 197.4, 167.8, 
144.5, 132.9, 132.8, 132.6, 132.5, 131.7, 126.6, 119.6, 115.6, 75.7, 67.4, 62.9, 61.1, 
45.5, 43.5, 43.2, 40.1, 32.5, 31.2, 30.1, 22.5, 17.8; ESIMS m/z 467.2 [M+H]+; 
HRESIMS m/z 489.1682 [M+Na]+ (calcd for C27H27NaFO6 489.1684). 
 
 Cytotoxicity Determination. The inhibitory effect of compounds on human cancer 
cell growth was determined using a colorimetric MTT assay. Briefly, the cell lines 
(MGC-803, Bel-7402, MCF-7, and K562; purchased from ATCC) were incubated at 
37 °C in a humidified 5% CO2 incubator for 24 h in 96-microwell plates prior to the 
experiments. After medium removal, 100 μL of fresh medium containing the test 
compound at different concentrations were added to each well and incubated at 37 °C 
for 48 or 72 h. The percentage of DMSO in the medium did not exceed by 0.25%. The 
number of living cells after 72 h (or 48 h) of culture in the presence (or absence: 
control) of the various compounds was directly proportional to the intensity of the 
purple color generated, which was measured quantitatively by spectrophotometry at a 
570 nm wavelength. The experiment was performed in quadruplicate and repeated 
three times. 
 
 Colony Formation Assay. Initially, 300 MCF-7 cells were plated per well in 30 
mm plates. After an overnight incubation, the cells were treated with various 
concentrations of 7b dissolved in DMSO. As a negative control, some cells were 
treated with vehicle (DMSO) only. After 24 h, the medium was removed and cells 
were allowed to grow for ten days. Subsequently, the cells were fixed with methanol 
for 15 min and stained with 0.1% crystal violet for 15 min. After removing the crystal 
violet by washing, the plates were photographed and counted, with one colony 
defined to be an aggregate of >50 cells. At least three independent experiments were 
performed for each assay. 
 
 Cell Cycle Analysis. Altogether, 5×104 cells were seeded into each well of a 
six-well plate and incubated overnight. Cells then were treated with various 
concentrations of each test compound for 48 h. The cells were harvested, washed with 
cold PBS, and then fixed with 70% ethanol in PBS at -20 °C for 12 h. Subsequently, 
the cells were resuspended in PBS containing 100 μg/mL RNase and 50 μg/mL PI and 
incubated at 37 °C for 30 min. Cell cycle distribution of nuclear DNA was determined 
by flow cytometry on an FC500 cytometer (Beckman Coulter). 
 
Cell Cytotoxicity. To measure cell cytotoxicity, MCF-7 and Bel-7402 cells were 
seeded at a density of ~5×103 cells per well in 96-well plates for 24 h, followed by 
incubation with the test compounds for 36 h. Then, the medium was collected and 
measured for cytotoxicity (LDH assay Kit; Promega), according to a standard 
protocol. The assay plate was allowed to equilibrate to ambient temperature, and 
CytoTox-ONETM reagent was added to each well and incubated for 10 min. Next, a 
stop solution was added, and the fluorescent signal was measured with an excitation 
wavelength of 560 nm and an emission wavelength of 590 nm. 
 
JC-1 Assay to Determine Mitochondrial Membrane Potential (MMP). The 
MMP was determined using the dual-emission mitochondrial dye JC-1. After 
treatment with various concentrations of 7b for 36 h, MCF-7 cells were loaded with 
10 µg/mL JC-1 dye for 30 min at 37 °C and then washed for 5 min in PBS buffer. 
After incubation, samples were immediately assessed for red and green fluorescence 
with a microplate reader or using fluorescence microscopy. The fluorescent signal of 
the monomers was measured at an excitation wavelength of 490 nm and an emission 
wavelength of 535 nm. The fluorescent signal of aggregates was detected with an 
excitation wavelength of 525 nm and an emission wavelength of 600 nm. All 
experiments were performed in triplicate. 
 
 Flow Cytometry Analysis of Apoptotic Cells. MCF-7 cells (1 × 105/well) were 
cultured in complete medium in six-well plates for 24 h and treated in triplicate with 
different concentrations of 7b for 24 h. The control cells were treated with vehicle (1‰ 
DMSO in complete medium). The cells were harvested, washed and stained with 
propidium iodide (PI), and FITC-Annexin V in the dark for 15 min using the 
FITC-AnnexinV Kit (BD Parmingen, San Diego, CA, USA). The percentages of 
apoptotic cells were determined by flow cytometry on an FC500 cytometer (Beckman 
Coulter). 
 
Western Blotting Analysis. MCF-7 cells were incubated in the presence of 7b and 
collected after 48 h. Cells were centrifuged and washed two times with ice-cold 
phosphate buffered saline. The pellet was then resuspended in lysis buffer. After the 
cells were lysed on ice for 20 min, lysates were centrifuged at 13,000 g at 4 °C for 15 
min. The protein concentration in the supernatant was determined using the BCA 
protein assay reagent. Equal amounts of protein (20 µg) were resolved using sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (8-12% acrylamide 
gel) and transferred to PVDF Hybond-P membrane. Membranes were blocked for 1 h 
at room temperature. Membranes were then incubated with primary antibodies against 
caspase-3, pro-caspase-3, Bax, Bcl-2, p-ERK, P53, β-actin, with gentle rotation 
overnight at 4 °C. Membranes were next incubated with fluorescent secondary 
antibodies for 60 min.  
 
In Vivo Tumor Xenograft Study. Five-week-old male Institute for Cancer 
Research (ICR) mice were purchased from Shanghai SLAC Laboratory Animals Co. 
Ltd. Altogether, 1×106 H22 cells were inoculated subcutaneously into the right flank 
of ICR mice according to a standard protocol, to initiate tumor growth. After 7 days of 
tumor transplantation, mice in the H22 group were weighted and divided into four 
groups of eight animals at random. The groups of 7b were administered intravenously 
10 and 20 mg/kg in a vehicle of 10% DMF/2% poloxamer/88% saline. The 
positive-control group was treated with oridonin (1) (20 mg/kg) through intravenous 
injection. The negative control group received 0.9% normal saline through 
intravenous injection. Treatments were done at a frequency of intravenous injection of 
one dose per day for a total 14 consecutive days. Body weights and tumor volumes 
were measured every two days. After the treatments, all of the mice were sacrificed 
and weighed. The following formula was used to determine tumor volumes: tumor 
volume = L×W2/2, where L is the length and W the width. Ratio of inhibition of tumor 
(%) = (1 – average tumor weight of treated group/average tumor weight of control 
group) × 100%. All procedures were performed in accordance with the NIH Guide for 
the Care and Use of Laboratory Animals. All animal handling and procedures were 
approved by the Ethical Committee of the China Pharmaceutical University (No. 
SYXK2016-0011). 
 
Statistics. Statistical analyses were performed using Graphpad Prism (San Diego, 
CA, USA). The results were expressed as means ± standard deviations (SD). Student’s 
t-test was employed to determine the statistical differences, and results were considerd 
statistically significant at the level of *p < 0.05, **p < 0.01, or ***p < 0.0001.  
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